The Food and Drug Administration moved to replace Dr. Tracy Beth Hoeg, who led the agency’s drug center portfolio, after Hoeg told staff and the public she was fired. Dr. Mike Davis is set to serve as acting drug center director, according to an email obtained by the Associated Press. Hoeg’s departure follows a broader period of FDA leadership disruption, including FDA Commissioner Marty Makary’s resignation and Dr. Vinay Prasad stepping down earlier after intense criticism from drugmakers, patients, and investors. Hoeg had led investigations into the safety of injectable RSV drugs for children, antidepressants, and COVID-19 vaccinations. The FDA changes come against complaints from President Donald Trump’s political allies, including anti-abortion groups and vaping lobbyists, who argued the agency’s direction did not match their priorities. The FDA also announced Karim Mikhail will lead as acting director of the vaccines center. For universities with medical research and health-policy stakeholders, these developments can affect regulatory timelines, research compliance expectations, and how public-facing safety reviews are managed across major therapeutic categories.